Updated on 2025/01/23

Information

 

写真a

 
NII TERUKI
 
Organization
Faculty of Engineering Department of Applied Chemistry Assistant Professor
School of Engineering （Concurrent）
Graduate School of Engineering （Concurrent）
Title
Assistant Professor
Contact information
メールアドレス
Profile
生体材料やドラッグデリバリーシステムを活用した再生医療研究を行っている。特に、最近では細胞医薬の開発を行っている。
External link

Degree

  • Ph.D.

Research Interests・Research Keywords

  • Research theme： Cancer therapy by using engineered macrophages-MacTrigger-

    Keyword： Cancer therapy

    Research period： 2022.4

  • Research theme： Novel therapy using engineered cells as a drug

    Keyword： DDS

    Research period： 2021.4

  • Research theme： Drug development using gelatin that can be eaten

    Keyword： DDS

    Research period： 2021.4

  • Research theme： 3D cell culture utilizing DDS technology

    Keyword： Tissue Engineering

    Research period： 2018.4 - 2021.3

  • Research theme： DDS formulation for therapy

    Keyword： DDS

    Research period： 2015.4

Awards

  • FBCAP最優秀賞

    2024.2   福岡バイオコミュニティ  

  • FBCAP 最優秀賞

    2024.2  

    新居 輝樹

    　More details

  • Cancers 2023 Outstanding Reviewer Award

    2023.4  

  • 再生医療研究奨励賞本賞

    2022.10  

  • 公益財団法人 池谷科学技術振興財団 単年度研究助成

    2022.4  

  • 上原記念生命科学財団 研究奨励賞

    2022.3  

  • 上原記念生命科学財団 研究奨励賞

    2022.3  

    新居 輝樹

    　More details

  • SNPEE Presentation Award

    2020.5   日本薬剤学会  

  • 日本薬剤学会永井財団大学院学生スカラシップ

    2020.5   日本薬剤学会  

  • 優秀ポスター発表賞

    2019.10   日本再生医療学会  

▼display all

Papers

  • Engineered macrophages acting as a trigger to induce inflammation only in tumor tissues Reviewed International journal

    Kenta Tanito, Teruki Nii, Yuta Yokoyama, Haruka Oishi, Mayuka Shibata, Shoichi Hijii, Ryosuke Kaneko, Chuya Tateishi, Shoko Ito, Akihiro Kishimura, Takeshi Mori, Yoshiki Katayama

    Journal of Controlled Release   361   885 - 895   2023.4

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    Herein, we report engineered macrophages, termed “MacTrigger,” acting as a trigger to induce an inflammatory environment only in tumor tissues. This led to intensive anti-tumor effects based on the removal potential of foreign substances. The strength of this study is the utilization of two unique functions of macrophages: (1) their ability to migrate to tumor tissues and (2) polarization into the anti-inflammatory M2 phenotype in the presence of tumor tissues. The MacTrigger accelerated the release of inflammatory cytokines, tumor necrosis factor-alpha (TNF-α), when it was polarized to the M2 phenotype. When the MacTrigger was administered to tumor-bearing mice, tumor growth was significantly inhibited compared with the non-treatment group, the un-transfected macrophages group, and the group with engineered macrophages capable of randomly releasing TNF-α. Additionally, the ratio of the M1 phenotype to the M2 phenotype in tumor tissues was >1 only in the MacTrigger group. Moreover, the ratios of natural killer cells and CD8+T cells in tumor tissues were increased compared with other groups. These results indicate that MacTrigger can induce inflammation in tumor tissues, leading to effective anti-tumor effects. In normal tissues, especially the liver, notable side effects were not observed. This is because, in the liver, the MacTrigger was not polarized to the M2 phenotype and could not induce inflammation. These results suggest that the MacTrigger is a “trigger” that can induce inflammation only in tumor tissues, then allowing the body to attack tumor tissues through the innate immunity system.

    DOI： 10.1016/j.jconrel.2023.04.010

  • Inflammation-Triggering Engineered Macrophages (MacTriggers) Enhance Reactivity of Immune Checkpoint Inhibitor Only in Tumor Tissues Reviewed

    Kenta Tanito, Teruki Nii, Kanae Wakuya, Yusuke Hamabe, Toma Yoshimi, Takanatsu Hosokawa, Akihiro Kishimura, Takeshi Mori, Yoshiki Katayama

    Cancers   16 ( 22 )   3787   2024.11   （ ISSN:2072-6694 eISSN:2072-6694 ）

    　More details

    Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：MDPI AG  

    Background: We have previously reported engineered macrophages (MacTriggers) that can accelerate the release of tumor necrosis factor-α in response to M2 polarization. MacTriggers are characterized by two original characteristics of macrophages: (1) migration to tumors; and (2) polarization to the M2 phenotype in tumors. Intravenously administered MacTriggers efficiently accumulated in the tumors and induced tumor-specific inflammation. This study reports a novel methodology for enhancing the anti-tumor effects of immune checkpoint inhibitors (ICIs). Results: In this study, we newly found that the intravenously administered MacTriggers in BALB/c mouse models upregulated the expression levels of immune checkpoint proteins, such as programmed cell death (PD)-1 in CD8+ T cells and PD-ligand 1 (PD-L1) in cancer cells and macrophages. Consequently, in two ICI-resistant tumor-inoculated mouse models, the combined administration of MacTrigger and anti-PD-1 antibody (aPD-1) synergistically inhibited tumor growth, whereas monotherapy with aPD-1 did not exhibit anti-tumor effects. This synergistic effect was mainly from aPD-1 enhancing the tumor-attacking ability of CD8+ T cells, which could infiltrate into the tumors following MacTrigger treatment. Importantly, no side effects were observed in normal tissues, particularly in the liver and spleen, indicating that the MacTriggers did not enhance the aPD-1 reactivity in normal tissues. This specificity was from the MacTriggers not polarizing to the M2 phenotype in normal tissues, thereby avoiding inflammation and increased PD-1/PD-L1 expression. MacTriggers could enhance aPD-1 reactivity only in tumors following tumor-specific inflammation induction. Conclusions: Our findings suggest that the MacTrigger and aPD-1 combination therapy is a novel approach for potentially overcoming the current low ICI response rates while avoiding side effects.

    DOI： 10.3390/cancers16223787

    Web of Science

    Scopus

    PubMed

    researchmap

  • In vitro evaluation of novel SN-38 prodrug activated by α-rhamnosidase of exogenous enzyme Reviewed

    Teruki Nii, Shoichi Hijii, Ryosuke Kaneko, Kenta Tanito, Kota Yamanaka, Akihiro Kishimura, Takeshi Mori, Yoshiki Katayama

    Analytical Sciences   40 ( 8 )   1529 - 1535   2024.8   （ ISSN:0910-6340 eISSN:1348-2246 ）

    　More details

    Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    This study introduces the α-rhamnose (Rham)-conjugated prodrug of SN-38 (Rham-SN-38) as a promising alternative to irinotecan. α-rhamnosidase, responsible for SN-38 release from Rham-SN-38, does not express in human cells, minimizing individual variability and side effects. The injection of the α-rhamnosidase into the tumor tissues makes it possible, for the first time, to activate the Rham-SN-38. Furthermore, α-rhamnosidase demonstrates significantly higher activity than carboxylesterase, the specific enzyme activating irinotecan. SN-38 release mediated by α-rhamnosidase completes within 2 h, with a kcat/Km value approximately 5.0 × 104-fold higher than that of irinotecan. The 50% inhibition concentration (IC50) of Rham-SN-38 against three types of cancer cells and one normal cell exceeds 4.5 × 103 nM. The addition of α-rhamnosidase significantly increases cytotoxicity, with IC50 comparable to free SN-38. The QIC50, an index reflecting the difference in cytotoxicity with and without α-rhamnosidase, exceeds approximately 1.0 × 102-fold. Rham-SN-38, synthesized in this study, demonstrates significant potential as a prodrug for cancer therapy. Graphical abstract: (Figure presented.)

    DOI： 10.1007/s44211-024-00593-9

    Web of Science

    Scopus

    PubMed

    researchmap

    Other Link： https://link.springer.com/article/10.1007/s44211-024-00593-9/fulltext.html

  • The effect of Fc region affinity of protein-based antibody-recruiting molecules on antibody-dependent cellular cytotoxicity Reviewed

    Hiroshi Tagawa, Riku Saeki, Chihaya Yamamoto, Kenta Tanito, Chihiro Tanaka, Shoki Munekawa, Teruki Nii, Akihiro Kishimura, Hiroshi Murakami, Takeshi Mori, Yoshiki Katayama

    RSC Advances   14 ( 32 )   22860 - 22866   2024.7   （ eISSN:2046-2069 ）

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Royal Society of Chemistry (RSC)  

    We report that novel protein-based Fc-binding antibody recruiting molecules (Fc-ARMs) with HER2-specific affibodies induce ADCC, but are less effective than conventional IgG-mediated ADCC and require further affinity improvement.

    DOI： 10.1039/d4ra03391d

    Web of Science

    Scopus

    PubMed

    researchmap

  • Oral Administration of PLGA Nanoparticles to Deliver Antisense Oligonucleotides to Inflammatory Lesions in the Gastrointestinal Tract Reviewed

    Yuta Yagi, Yiwei Liu, Jinting Li, Shunsuke Shimada, Munetaka Ohkouchi, Yasushi Taguchi, Teruki Nii, Takeshi Mori, Yoshiki Katayama

    Biological and Pharmaceutical Bulletin   47 ( 4 )   848 - 855   2024.4

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/bpb.b23-00769

  • Effective design of PEGylated polyion complex (PIC) nanoparticles for enhancing PIC internalisation in cells utilising block copolymer combinations with mismatched ionic chain lengths Reviewed International journal

    Fadlina Aulia, Hiroaki Matsuba, Shoya Adachi, Takumi Yamada, Ikuhiko Nakase, Teruki Nii, Takeshi Mori, Yoshiki Katayama, Akihiro Kishimura

    Journal of Materials Chemistry B   12   1826 - 1836   2024.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Orthogonality of α-Sulfoquinovosidase in Human Cells and Development of Its Fluorescent Substrate Reviewed

    Ryosuke Yoshida, Ryosei Kaguma, Ryosuke Kaneko, Ichiro Matuso, Makoto Yoritate, Go Hirai, Takamasa Teramoto, Yoshimitsu Kakuta, Kosuke Minamihata, Noriho Kamiya, Teruki Nii, Akihiro Kishimura, Takeshi Mori, Yoshiki Katayama

    Sensors and Materials   36 ( 8 )   3227 - 3238   2024   （ ISSN:0914-4935 eISSN:2435-0869 ）

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：MYU K.K.  

    Human orthogonal enzymes (HOEs) do not show the same activities as the endogenous enzymes of human cells and thus are useful as amplification enzymes to detect antigen proteins in biological samples. Here, we evaluate a new HOE from Escherichia coli, α-sulfoquinovosidase (α-SQase). We confirmed that the activity of α-SQase did not exist in examined human cell lines, and thus it was applicable to live-cell enzyme-linked immunosorbent assay (ELISA) in which the antigen membrane protein on cells was detected without inactivating endogenous enzymes, a pretreatment required for cell ELISA using conventional amplification enzymes. Here, we also developed a fluorescent substrate for α-SQase whose active residue is located at the end of the narrow, deep pocket of the substrate recognition site. The designed methylumbelliferyl substrate with a hydroxyl benzyl alcohol linker showed a similar reactivity to the p-nitrophenol substrate, a good substrate for α-SQase.

    DOI： 10.18494/SAM4816

    Web of Science

    Scopus

    researchmap

  • Dynamic frustrated charge hotspots created by charge density modulation sequester globular proteins into complex coacervates Reviewed

    Biplab K C, Teruki Nii, Takeshi Mori, Yoshiki Katayama, Akihiro Kishimura

    Chemical Science   14 ( 24 )   6608 - 6620   2023.6

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    This study presents a simple strategy for the sequestration of globular proteins as clients into synthetic polypeptide-based complex coacervates as a scaffold, thereby recapitulating the scaffold-client interaction found in biological...

    DOI： 10.1039/d3sc00993a

  • Development of New Sublingual Formulation for Transmucosal Delivery of Peptides Reviewed

    Keiko Minami, Makoto Kataoka, Toshihide Takagi, Teruki Nii, Yasuhiko Tabata, Shinji Yamashita

    YAKUGAKU ZASSHI   143 ( 4 )   345 - 348   2023.4

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1248/yakushi.22-00170-1

  • A human cell orthogonal enzyme β-D-galacturonidase for sensitive detection of antigen proteins Reviewed

    Chuya Tateishi, Akihiro Koga, Atsuhiro Matsuura, Ryosuke Kaneko, Kenta Tanito, Teruki Nii, Akihiro Kishimura, Takeshi Mori, Yoshiki Katayama

    The Analyst   2023.4

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    Enzymes are used to amplify signals for detection of antigen proteins in biological samples. However, the enzymes conventionally used for this purpose have limitations, such as the presence of the...

    DOI： 10.1039/d3an00314k

  • Characterization of polypropyleneimine as an alternative transfection reagent Reviewed

    Riku Saeki, Shingo Kobayashi, Rena Shimazui, Teruki Nii, Akihiro Kishimura, Takeshi Mori, Masaru Tanaka, Yoshiki Katayama

    Analytical Sciences   2023.3

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s44211-023-00284-x

  • Facile preparation of hexagonal nanosheets via polyion complex formation from α-helical polypeptides and polyphosphate-based molecules Reviewed

    Asmariah Ahmad, Tomoki Maruyama, Teruki Nii, Takeshi Mori, Yoshiki Katayama, Akihiro Kishimura

    Chemical Communications   59 ( 12 )   1657 - 1660   2023.1

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    The fabrication of regular hexagonal PIC nanosheets was achieved via induction of the α-helix secondary structure in a PEGylated catiomer promoted by complexation with polyphosphates.

    DOI： 10.1039/d2cc05137k

  • Three-dimensional culture system utilizing DDS technology

    Teruki Nii

    Drug Delivery System   37 ( 3 )   270 - 271   2022.10

    　More details

    Language：Others  

  • A Mouse Model for Tuberculosis Combined With Inhalable Imiquimod-PLGA Nanocomposite Particles Based on Macrophage Phenotype Reviewed

    TERUKI NII, SHUNSUKE TAKIZAWA, TOMOMI AKITA, CHIKAMASA YAMASHITA, ISSEI TAKEUCHI, KIMIKO MAKINO

    In Vivo   36 ( 5 )   2166 - 2172   2022.9

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.21873/invivo.12942

  • Three-dimensional culture system combined with drug delivery system

    Teruki Nii

    2nd Global Summit on Biomaterials and Applications   2022.8

    　More details

    Language：Others  

  • DDS技術に基づく3次元培養システム

    新居 輝樹

    日本DDS学会 機関誌「Drug Delivery System」   37 ( 3 )   270 - 271   2022.7

    　More details

    Language：Others  

  • Nanostructure Control of an Antibiotic‐Based Polyion Complex Using a Series of Polycations with Different Side‐Chain Modification Rates Reviewed

    Asmariah Ahmad, Teruki Nii, Takeshi Mori, Yoshiki Katayama, Masanori Toyofuku, Akihiro Kishimura

    Macromolecular Rapid Communications   43 ( 19 )   2200316 - 2200316   2022.6

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/marc.202200316

  • Preparation of Micelles Encapsulating Doxorubicin and Their Anticancer Effect in Combination With Tranilast in 3D Spheroids and In Vivo Reviewed

    TERUKI NII, KANJI YOSHIKAWA, ISSEI TAKEUCHI, KIMIKO MAKINO

    Anticancer Research   42 ( 6 )   2847 - 2857   2022.5

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.21873/anticanres.15766

  • Drug screening model utilizing 3D cell culture and drug release system

    Teruki Nii

    Functional Materials 2022   2022.4

    　More details

    Language：Others  

  • Poly(Alkyloxyethylene-Lactate Phosphate) for Delivery of Doxorubicin: Synthesis and Characterization Reviewed

    KANJI YOSHIKAWA, TERUKI NII, KOLIO TROEV, KIMIKO MAKINO, ISSEI TAKEUCHI

    Anticancer Research   42 ( 4 )   1801 - 1811   2022.3

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.21873/anticanres.15656

  • Efficient cell transplantation combining injectable hydrogels with control release of growth factors Reviewed

    Ryo Mitsui, Makoto Matsukawa, Kiyoko Nakagawa, Emiko Isomura, Toshie Kuwahara, Teruki Nii, Susumu Tanaka, Yasuhiko Tabata

    Regenerative Therapy   18   372 - 383   2021.12

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.reth.2021.09.003

  • Immunosuppressive mesenchymal stem cells aggregates incorporating hydrogel microspheres promote an in vitro invasion of cancer cells Reviewed

    Teruki Nii, Yasuhiko Tabata

    Regenerative Therapy   18   516 - 522   2021.12

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.reth.2021.11.006

  • Strategies Using Gelatin Microparticles for Regenerative Therapy and Drug Screening Applications Reviewed

    Teruki Nii

    Molecules   26 ( 22 )   6795 - 6795   2021.11

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    Gelatin, a denatured form of collagen, is an attractive biomaterial for biotechnology. In particular, gelatin particles have been noted due to their attractive properties as drug carriers. The drug release from gelatin particles can be easily controlled by the crosslinking degree of gelatin molecule, responding to the purpose of the research. The gelatin particles capable of drug release are effective in wound healing, drug screening models. For example, a sustained release of growth factors for tissue regeneration at the injured sites can heal a wound. In the case of the drug screening model, a tissue-like model composed of cells with high activity by the sustained release of drug or growth factor provides reliable results of drug effects. Gelatin particles are effective in drug delivery and the culture of spheroids or cell sheets because the particles prevent hypoxia-derived cell death. This review introduces recent research on gelatin microparticles-based strategies for regenerative therapy and drug screening models.

    DOI： 10.3390/molecules26226795

  • α-L-Arabinofuranosidase as an Orthogonal Enzyme for Human Cells Reviewed

    Ryosuke Kaneko, Tsuyoshi Oda, Ryosuke Yoshida, Chuya Tateishi, Kenta Tanito, Teruki Nii, Akihiro Kishimura, Noriho Kamiya, Takeshi Mori, Yoshiki Katayama

    Chemistry Letters   50 ( 8 )   1493 - 1495   2021.8

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

  • Biomaterial-Assisted Regenerative Medicine Reviewed

    Teruki Nii, Yoshiki Katayama

    International Journal of Molecular Sciences   22 ( 16 )   8657 - 8657   2021.8

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    This review aims to show case recent regenerative medicine based on biomaterial technologies. Regenerative medicine has arousing substantial interest throughout the world, with “The enhancement of cell activity” one of the essential concepts for the development of regenerative medicine. For example, drug research on drug screening is an important field of regenerative medicine, with the purpose of efficient evaluation of drug effects. It is crucial to enhance cell activity in the body for drug research because the difference in cell condition between in vitro and in vivo leads to a gap in drug evaluation. Biomaterial technology is essential for the further development of regenerative medicine because biomaterials effectively support cell culture or cell transplantation with high cell viability or activity. For example, biomaterial-based cell culture and drug screening could obtain information similar to preclinical or clinical studies. In the case of in vivo studies, biomaterials can assist cell activity, such as natural healing potential, leading to efficient tissue repair of damaged tissue. Therefore, regenerative medicine combined with biomaterials has been noted. For the research of biomaterial-based regenerative medicine, the research objective of regenerative medicine should link to the properties of the biomaterial used in the study. This review introduces regenerative medicine with biomaterial.

    DOI： 10.3390/ijms22168657

  • Design of an anti-cancer drug screening model combined with three-dimensional cell culture and drug release system

    Teruki Nii

    2021.3

    　More details

    Language：Others  

  • Web対談 : SNPEE2020 "Diversity～薬剤学の色んな『か・た・ち』を学ぼう～"

    新居 輝樹

    学会誌「薬剤学」   81 ( 1 )   26 - 33   2021.1

    　More details

    Language：Others  

  • A Co-Culture System of Three-Dimensional Tumor-Associated Macrophages and Three-Dimensional Cancer-Associated Fibroblasts Combined with Biomolecule Release for Cancer Cell Migration Reviewed

    Teruki Nii, Toshie Kuwahara, Kimiko Makino, Yasuhiko Tabata

    Tissue Engineering Part A   26 ( 23-24 )   1272 - 1282   2020.12

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1089/ten.tea.2020.0095

  • Three-Dimensional Culture System of Cancer Cells Combined with Biomaterials for Drug Screening Reviewed

    Teruki Nii, Kimiko Makino, Yasuhiko Tabata

    Cancers   12 ( 10 )   2754 - 2754   2020.9

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    Anticancer drug screening is one of the most important research and development processes to develop new drugs for cancer treatment. However, there is a problem resulting in gaps between the in vitro drug screening and preclinical or clinical study. This is mainly because the condition of cancer cell culture is quite different from that in vivo. As a trial to mimic the in vivo cancer environment, there has been some research on a three-dimensional (3D) culture system by making use of biomaterials. The 3D culture technologies enable us to give cancer cells an in vitro environment close to the in vivo condition. Cancer cells modified to replicate the in vivo cancer environment will promote the biological research or drug discovery of cancers. This review introduces the in vitro research of 3D cell culture systems with biomaterials in addition to a brief summary of the cancer environment.

    DOI： 10.3390/cancers12102754

  • A cancer invasion model of cancer-associated fibroblasts aggregates combined with TGF-β1 release system Reviewed

    Teruki Nii, Kimiko Makino, Yasuhiko Tabata

    Regenerative Therapy   14   196 - 204   2020.6

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.reth.2020.02.003

  • DDS技術を組み込んだがん浸潤・転移を再現するための細胞培養法の創出～再生医療への薬学分野の1つの貢献～

    新居 輝樹

    日本薬剤学会第35年会   100   2020.5

    　More details

    Language：Others  

  • A Cancer Invasion Model Combined with Cancer-Associated Fibroblasts Aggregates Incorporating Gelatin Hydrogel Microspheres Containing a p53 Inhibitor Reviewed

    Teruki Nii, Kimiko Makino, Yasuhiko Tabata

    Tissue Engineering Part C: Methods   25 ( 12 )   711 - 720   2019.12

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1089/ten.tec.2019.0189

  • Influence of shaking culture on the biological functions of cell aggregates incorporating gelatin hydrogel microspheres Reviewed

    Teruki Nii, Kimiko Makino, Yasuhiko Tabata

    Journal of Bioscience and Bioengineering   128 ( 5 )   606 - 612   2019.11

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jbiosc.2019.04.013

  • Effects of the conformation of PLGA molecules in the organic solvent on the aerodynamic diameter of spray dried microparticles Reviewed

    Teruki Nii, Issei Takeuchi, Yukie Kimura, Kimiko Makino

    Colloids and Surfaces A: Physicochemical and Engineering Aspects   539   347 - 353   2018.2

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.colsurfa.2017.12.042

  • Inhalable nanocomposite particles using amino acids with improved drug content and humidity resistance Reviewed

    Issei Takeuchi, Yumi Tetsuka, Teruki Nii, Masayuki Shinogase, Kimiko Makino

    Colloids and Surfaces A: Physicochemical and Engineering Aspects   529   387 - 393   2017.9

    　More details

    Language：Others   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.colsurfa.2017.06.003

▼display all

Books

  • 生体に腫瘍を排除させるトリガーとして機能する遺伝子改変マクロファージ『マックトリガー』

    新居　輝樹（Role：Sole author）

    バイオインダストリー  2024.3 

    　More details

    Responsible for pages：21-29   Language：Japanese   Book type：Scholarly book

  • DDS技術に基づく3次元培養システム

    新居　輝樹

    2022.6 

    　More details

    Language：Japanese  

Presentations

  • 遺伝子改変マクロファージが拓くがん治療コンセプト Invited

    新居　輝樹

    第74回医用高分子研究会  2024.3 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • 腫瘍で炎症のトリガーとして機能するマクロファージ医薬“MacTrigger” Invited

    新居　輝樹、谷戸　謙太、岸村　顕広、森　健、片山　佳樹

    第44回日本炎症再生医学会  2023.7 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • 腫瘍で炎症のトリガーとして機能するマクロファージ医薬「MacTrigger」 Invited

    新居　輝樹、谷戸　謙太、岸村　顕広、森　健、片山　佳樹

    第72回高分子討論会  2023.9 

    　More details

    Event date： 2024.4

    Language：Japanese  

    Country：Japan  

  • 舌下適用型製剤によるペプチド医薬品の新たな投与法の開発：デスモプレシン舌下ゼリー剤

    水川 皓介, 南 景子, 片岡 誠, 高木 敏英, 田中 雅幸, 田畑 泰彦, 新居 輝樹, 菱川 慶裕, 山下 伸二

    日本薬剤学会第36年会  2021.5 

    　More details

    Event date： 2021.5

    Language：Others  

    Country：Other  

  • 抗がん剤内包ミセル製剤とトラニラスト併用によるがん細胞スフェロイドへの薬物浸透性の向上

    吉川 莞爾, 竹内 一成, 新居 輝樹, 牧野 公子

    日本油化学会第58回年会  2020.11 

    　More details

    Event date： 2020.11

    Language：Japanese  

    Country：Japan  

  • TGF-β1徐放を活用したがん浸潤の試験管内での再現

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第36回日本DDS学会学術集会  2020.8 

    　More details

    Event date： 2020.8

    Language：Japanese  

    Country：Japan  

  • がん関連マクロファージの3次元培養とスクリーニングモデルへの応用

    新居 輝樹, 桑原 寿江, 牧野 公子, 田畑 泰彦

    第41回日本炎症・再生医学会  2020.7 

    　More details

    Event date： 2020.7

    Language：Japanese  

    Country：Japan  

  • DDS技術を組み込んだがん浸潤・転移を再現するための細胞培養法の創出～再生医療への薬学分野の1つの貢献～ Invited

    新居 輝樹, 牧野 公子, 田畑 泰彦

    日本薬剤学会第35年会  2020.5 

    　More details

    Event date： 2020.5

    Language：Japanese  

    Country：Japan  

  • 創薬研究のための組織工学技術を組み込んだ3次元細胞培養法のデザイン

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第19回日本再生医療学会総会  2020.3 

    　More details

    Event date： 2020.3

    Language：Japanese  

    Country：Japan  

  • 「3次元培養とDDS技術の融合」によるがん浸潤現象の試験管内での再現

    新居 輝樹, 牧野 公子, 田畑 泰彦

    日本薬学会第140年会  2020.3 

    　More details

    Event date： 2020.3

    Language：Japanese  

    Country：Japan  

  • 新規リン酸エステルポリマーミセル製剤の開発とその評価のためのがん細胞-線維芽細胞共培養系の作製

    吉川 莞爾, 新居 輝樹, 竹内 一成, 牧野 公子

    日本薬学会第140年会  2020.3 

    　More details

    Event date： 2020.3

    Language：Japanese  

    Country：Japan  

  • DDS技術と3次元培養を組み合わせた抗がん剤スクリーニングモデル

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第3回がん三次元培養研究会  2019.11 

    　More details

    Event date： 2019.11

    Language：Japanese  

    Country：Japan  

  • 薬物徐放ゼラチンハイドロゲル粒子と3次元培養を組み合わせた抗がん剤スクリーニングモデル

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第41回日本バイマテリアル学会  2019.11 

    　More details

    Event date： 2019.11

    Language：Japanese  

    Country：Japan  

  • 組織工学技術を組み込んだ3D細胞培養を活用した創薬がん浸潤モデル

    新居 輝樹, 牧野 公子, 田畑 泰彦

    日本再生医療学会第1回秋季科学シンポジウム  2019.10 

    　More details

    Event date： 2019.10

    Language：Japanese  

    Country：Japan  

  • がん浸潤モデルの創製：3次元細胞培養とDDS技術の融合

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第63回日本薬学会関東支部大会  2019.9 

    　More details

    Event date： 2019.9

    Language：Japanese  

    Country：Japan  

  • 3次元細胞培養と細胞活性化薬物徐放を組み合わせたがん浸潤モデルの創製

    新居 輝樹, 牧野 公子, 田畑 泰彦

    日本油化学会第58回年会  2019.9 

    　More details

    Event date： 2019.9

    Language：Japanese  

    Country：Japan  

  • がん浸潤モデルのためのがん関連線維芽細胞活性化薬物の徐放化

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第35回日本DDS学会学術集会  2019.7 

    　More details

    Event date： 2019.7

    Language：Japanese  

    Country：Japan  

  • 浸潤モデルとしてのDDS技術を組み合わせた3次元がん関連線維芽細胞培養

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第28回日本がん転移学会学術集会・総会  2019.7 

    　More details

    Event date： 2019.7

    Language：Japanese  

    Country：Japan  

  • ゼラチンハイドロゲル粒子含有細胞凝集体の細胞機能に与える培養方法の影響

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第40回日本炎症・再生医学会  2019.7 

    　More details

    Event date： 2019.7

    Language：Japanese  

    Country：Japan  

  • 薬物徐放粒子を含むがん関連線維芽細胞3次元凝集体を用いたがん浸潤モデル

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第23回日本がん分子標的治療学会学術集会  2019.6 

    　More details

    Event date： 2019.6

    Language：Japanese  

    Country：Japan  

  • 3次元細胞培養とDDS技術を組み合わせたがん浸潤モデルの創製

    新居 輝樹, 牧野 公子, 田畑 泰彦

    日本薬剤学会第34年会  2019.5 

    　More details

    Event date： 2019.5

    Language：Japanese  

    Country：Japan  

  • 薬物徐放粒子を組み込んだがん細胞-線維芽細胞3次元凝集体の作製

    新居 輝樹, 牧野 公子, 田畑 泰彦

    日本薬学会第139年会  2019.3 

    　More details

    Event date： 2019.3

    Language：Japanese  

    Country：Japan  

  • ゼラチンハイドロゲル粒子を含む細胞凝集体の振盪培養

    新居 輝樹, 牧野 公子, 田畑 泰彦

    第40回日本バイマテリアル学会  2018.11 

    　More details

    Event date： 2018.11

    Language：Japanese  

    Country：Japan  

  • 溶液中におけるPLGA分子挙動がマイクロ粒子の空気力学的粒子径に与える影響

    新居 輝樹, 竹内 一成, 牧野 公子

    第34回日本DDS学会学術集会  2018.6 

    　More details

    Event date： 2018.6

    Language：Japanese  

    Country：Japan  

  • Pulmonary drug delivery for treatment of tuberculosis: impact of the motion of PLGA molecules in the feed solution on FPF of spray dried microparticles International conference

    Teruki Nii, Issei Takeuchi, Takehisa Nakajima, Kimiko Makino

    International symposium on drug delivery and pharmaceutical sciences: beyond the history  2017.2 

    　More details

    Event date： 2017.2

    Language：English   Presentation type：Oral presentation (general)  

    Country：Japan  

  • 新規膜アンカーペプチド探索のためのGFP-pHLIPの腫瘍標的化

    谷戸 謙太, 田川寛, 新居輝樹, 岸村顕広, 森健, 片山佳樹

    第31回バイオ・高分子シンポジウム  2021.6 

    　More details

    Language：Others  

    Country：Other  

  • ペプチド医薬品の新規投与システムの開発：舌下適用型ゼリー剤

    南 景子, 片岡 誠, 高木 敏英, 田中 雅幸, 田畑 泰彦, 新居 輝樹, 菱川 慶裕, 山下 伸二

    第37回日本DDS学会学術集会  2021.6 

    　More details

    Language：Others  

    Country：Other  

  • バイオ分析に利用可能なヒト細胞直交性の加水分解酵素の開拓

    金子 諒右, 立石 宙也, 谷戸 謙太, 新居 輝樹, 岸村 顕広, 神谷 典穂, 森 健, 片山 佳樹

    日本ケミカルバイオロジー学会 第15回年会  2021.6 

    　More details

    Language：Others  

    Country：Other  

  • TGF-β1 含浸ゼラチンハイドロゲル粒子を組み込んだ3次元線維芽細胞凝集体の調製

    堀下 駿太, 新居 輝樹, 田畑 泰彦

    第67回高分子研究発表会(神戸)  2021.7 

    　More details

    Language：Others  

    Country：Other  

▼display all

Industrial property rights

Patent   Number of applications: 4   Number of registrations: 0
Utility model   Number of applications: 0   Number of registrations: 0
Design   Number of applications: 0   Number of registrations: 0
Trademark   Number of applications: 0   Number of registrations: 0

Professional Memberships

  • 日本DDS学会

  • 日本バイオマテリアル学会

  • 日本再生医療学会

  • 日本炎症・再生医学会

  • 日本薬剤学会

  • 日本薬学会

  • 日本分析化学会

▼display all

Research Projects

  • 免疫抑制環境を破壊してトリプルネガティブ乳がんを治療するマクロファージ医薬の開発

    2024.10 - 2027.3

    AMED  革新的がん医療実用化研究事業 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive funding other than Grants-in-Aid for Scientific Research

  • 腫瘍で炎症のトリガーとして機能する遺伝子改変マクロファージの最適化

    2024.8 - 2025.8

    JST  Platform for All Regions of Kyushu & Okinawa for Startup-ecosystem (PARKS) 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive funding other than Grants-in-Aid for Scientific Research

  • iPS細胞由来マクロファージに関する研究

    2024.4 - 2025.4

    　 More details

    Grant type：Other funds from industry-academia collaboration

  • 薬効の適切なon-offスイッチを細胞が担うがん治療戦略

    Grant number：24K21087  2024 - 2026

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Early-Career Scientists

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • 野口遵研究助成金

    2024

    　 More details

    Grant type：Donation

  • 池谷科学技術振興財団 単年度研究助成

    2024

    　 More details

    Grant type：Donation

  • AMED 橋渡し研究プログラム

    2024

    　 More details

    Grant type：Donation

  • 公益財団法人 上原記念生命科学財団　2023年度　研究奨励金

    2023

    　 More details

    Grant type：Donation

  • 公益財団法人 テルモ生命科学振興財団　2023年度　研究開発助成

    2023

    　 More details

    Grant type：Donation

  • 標的細胞内でのアレルゲン徐放に基づくアレルギー治療薬の開発

    Grant number：22K18197  2022 - 2024

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Early-Career Scientists

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • 令和４年度 工学研究新分野開拓助成

    2022 - 2023

    　 More details

    Grant type：On-campus funds, funds, etc.

  • 池谷科学技術振興財団 単年度研究助成

    2022

    　 More details

    Grant type：Donation

  • 池田理化　再生医療研究奨励賞　本賞

    2022

    　 More details

    Grant type：Donation

  • 令和2〜6年度 文部科学省科学研究費助成事業 学術変革領域研究（Ａ）「物質共生」

    2021.4 - 2024.3

  • 抗がん剤スクリーニングモデルに向けた成長因子の徐放技術を活用した3次元組織体の構築

    Grant number：21K20517  2021 - 2022

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Research Activity start-up

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • 上原記念生命科学財団 研究奨励金

    2021

    　 More details

    Grant type：Donation

▼display all

Social Activities

  • 大学での学び

    福岡大学附属大濠高等学校  2022.11

    　More details

    Audience：Infants,　Schoolchildren,　Junior students,　High school students

    Type：Seminar, workshop

Media Coverage

  • 九大、がん選択的に炎症を起こすマクロファージを構築 Newspaper, magazine

    日経バイオテク  2023.10

    　More details

    九大、がん選択的に炎症を起こすマクロファージを構築

  • 九大、がん選択的に炎症を起こすマクロファージを構築 Internet

    日経バイオテク  2023.10

    　More details

  • 副作用がほとんどないがんの新しい治療法「マックトリガー」とは？ Newspaper, magazine

    小学館 DIME  2023.8

    　More details

    副作用がほとんどないがんの新しい治療法「マックトリガー」とは？

  • 副作用がほとんどないがんの新しい治療法「マックトリガー」とは？ Newspaper, magazine

    小学館 DIME  2023.8

    　More details

  • マックトリガー Newspaper, magazine

    小学館  DIME  2023.7

    　More details

  • がんの免疫抑制をぶっ壊す

    医薬経済  2023.6

    　More details

    がんの免疫抑制をぶっ壊す

  • Attacking cancer cells by activating inflammation — Kyushu University develops new theoretical method for cancer treatment

    Science Japan (JST)  2023.6

    　More details

    Attacking cancer cells by activating inflammation — Kyushu University develops new theoretical method for cancer treatment

  • がんの免疫抑制をぶっ壊す Newspaper, magazine

    医薬経済  2023.6

    　More details

    がんの免疫抑制をぶっ壊す

  • がんの免疫抑制をぶっ壊す Internet

    医薬経済  2023.6

    　More details

  • 九州大学、ヒトの拒絶反応を利用してがん細胞を炎症組織に変換しがんを除去 Newspaper, magazine

    客観日本 (JST)  2023.5

    　More details

    九州大学、ヒトの拒絶反応を利用してがん細胞を炎症組織に変換しがんを除去

  • 九州大学、ヒトの拒絶反応を利用してがん細胞を炎症組織に変換しがんを除去

    2023.5

    　More details

    九州大学、ヒトの拒絶反応を利用してがん細胞を炎症組織に変換しがんを除去

  • がん細胞を炎症組織に変えて攻撃 使うのは生体の異物排除機能 九州大が治療薬に頼らぬ手法開発

    科学新聞  2023.5

    　More details

    がん細胞を炎症組織に変えて攻撃 使うのは生体の異物排除機能 九州大が治療薬に頼らぬ手法開発

  • がんでのみ強力な炎症を引き起こす「細胞医薬」の開発に成功

    医療総合サイトQLife  2023.5

    　More details

    がんでのみ強力な炎症を引き起こす「細胞医薬」の開発に成功

  • がんでのみ強力な炎症を引き起こす「細胞医薬」の開発に成功 Internet

    医療総合サイトQLife  2023.5

    　More details

  • 九州大学将癌细胞转化为炎症组织，利用人体排异消灭癌症 Newspaper, magazine

    客観日本 (JST)  2023.5

    　More details

  • がん細胞を炎症組織に変えて攻撃 使うのは生体の異物排除機能 九州大が治療薬に頼らぬ手法開発 Newspaper, magazine

    科学新聞  2023.5

    　More details

  • がん特異的に強力な炎症を引き起こす細胞医薬「MacTrigger」を開発－九大

    QLifePro医療ニュース  2023.4

    　More details

    がん特異的に強力な炎症を引き起こす細胞医薬「MacTrigger」を開発－九大

  • 炎症反応で免疫細胞活性化 がんの成長抑える物質開発 九州大

    2023.4

    　More details

    炎症反応で免疫細胞活性化 がんの成長抑える物質開発 九州大

  • 九州大学が世界初のがん治療法を開発 患者自身の免疫機能使い“大きな副作用なし” 福岡市

    2023.4

    　More details

    九州大学が世界初のがん治療法を開発 患者自身の免疫機能使い“大きな副作用なし” 福岡市

  • 九大、がんを退治する“引き金”を投与する細胞医薬法の開発に成功

    マイナビニュース  2023.4

    　More details

    九大、がんを退治する“引き金”を投与する細胞医薬法の開発に成功

  • 世界初！からだ自身が“がん治療” 九州大学が開発

    2023.4

    　More details

    世界初！からだ自身が“がん治療” 九州大学が開発

  • がん特異的に強力な炎症を引き起こす細胞医薬「MacTrigger」を開発－九大 Internet

    QLifePro医療ニュース  2023.4

    　More details

  • 九州大学が世界初のがん治療法を開発 患者自身の免疫機能使い“大きな副作用なし” 福岡市 TV or radio program

    テレビ西日本  2023.4

    　More details

  • 九大、がんを退治する“引き金”を投与する細胞医薬法の開発に成功 Internet

    マイナビニュース  2023.4

    　More details

  • 世界初！からだ自身が“がん治療” 九州大学が開発 TV or radio program

    九州朝日放送  2023.4

    　More details

  • 【2022年度 池田理化賞】九州大学・新居先生 採択者インタビュー

    IKEDA_ONLINE  2023.2

    　More details

    【2022年度 池田理化賞】九州大学・新居先生 採択者インタビュー

▼display all